Compare · MPLT vs NVO
MPLT vs NVO
Side-by-side comparison of MapLight Therapeutics Inc. (MPLT) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MPLT and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $191.82B, about 151.0x MPLT ($1.27B).
- Over the past year, MPLT is up 53.6% and NVO is down 43.1% - MPLT leads by 96.7 points.
- NVO has been more active in the news (7 items in the past 4 weeks vs 3 for MPLT).
- NVO has more recent analyst coverage (25 ratings vs 10 for MPLT).
- Company
- MapLight Therapeutics Inc.
- Novo Nordisk A/S
- Price
- $28.07-6.31%
- $42.94-1.84%
- Market cap
- $1.27B
- $191.82B
- 1M return
- -3.37%
- -6.14%
- 1Y return
- +53.64%
- -43.10%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2025
- News (4w)
- 3
- 7
- Recent ratings
- 10
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest MPLT
- UBS initiated coverage on MapLight Therapeutics with a new price target
- Craig Hallum initiated coverage on MapLight Therapeutics with a new price target
- Chief Executive Officer Kroeger Christopher A. sold $3,215,000 worth of Voting Common Stock (118,235 units at $27.19) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 1,394,094 units (SEC Form 4)
- SEC Form 10-Q filed by MapLight Therapeutics Inc.
- MapLight Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- MapLight Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
- Chief Medical Officer Foff Erin Pennock sold $126,640 worth of Voting Common Stock (4,438 units at $28.54) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 346,059 units (SEC Form 4)
- General Counsel Hanson Kristopher sold $419,263 worth of Voting Common Stock (13,917 units at $30.13) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 162,331 units (SEC Form 4)
- Chief Executive Officer Kroeger Christopher A. sold $1,949,634 worth of Voting Common Stock (68,491 units at $28.47) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 1,512,329 units (SEC Form 4)
- Chief Scientific Officer Lillie James Woodruff sold $20,390 worth of Voting Common Stock (721 units at $28.28) as part of a pre-agreed trading plan, decreasing direct ownership by 0.30% to 242,729 units (SEC Form 4)
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care
- Peptide Wellness Market Could Near $300 Billion as Consumer Demand Accelerates